Miquel Angel Bonachera and Sergi Audivert, co-founders and CEOs of AB-Biotics, said: “The agreement with GlaxoSmithKline will be a major boost for the AB-Biotics turnover in the coming years.”
GSK will promote in Brazil Neurofarmagen, a genetic test developed by AB-Biotics which identifies the safest and most appropriate medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva.
The product will be launched this year in Brazil, where according to estimates by AB-Biotics, there are one million potential patients eligible for Neurofarmagen. In Spain, this test is currently marketed by Almirall following the agreement signed last October by this Spanish pharmaceutical company and AB-Biotics.
Source: AB-Biotics
© FoodBev Media Ltd 2024